PhotonPharma Inc, a developer of autologous cancer immunotherapies, announced on Thursday the appointment of William Warren, Ph.D. to its board of directors.
PhotonPharma says that Dr. Warren brings more than three decades of experience in biotechnology innovation, vaccine development, and successful entrepreneurship to guide the company's strategic initiatives and growth trajectory.
Most recently, Dr. Warren served in multiple senior leadership roles at Sanofi Vaccines R&D, including head of Innovation, leading a virtual biotech to advance next-generation influenza vaccines, and head of Global Antigen Design, where his group was responsible for antigen designs to advance projects, invigorate an innovative culture, and explore biology and technology interfaces.
Prior to Sanofi, Dr. Warren was CEO and co-founder of VaxDesign Corporation, which he led through its acquisition by Sanofi in 2010. He also co-founded nScrypt Inc, a company specialising in advanced 3D printing and bioprinting systems, and was a managing partner of Sciperio Inc, an innovative high-technology development company.
Immunovia gains California approval for PancreaSure and begins commercial rollout
Profusa launches Lumee tissue oxygen system for CRO market
OncoHost receives BIG Innovation Award in Health category
Hoth Therapeutics achieves European regulatory milestone for HT-001
AVEO Oncology reports first patient dosed in front-line AML combination study of ficlatuzumab
Rakuten Medical signs manufacturing agreement with LOTTE Biologics
Curasight reports preliminary data from Phase 1 trial in patients with high-grade gliomas